Oxford Biomedica's ProSavin® - Clinical Trial Application (CTA) Update.

"As reported, Oxford BioMedica submitted a CTA to conduct a Phase I/II trial of ProSavin to the French Health Products Safety Agency (AFSSAPS) in July 2007 following several scientific meetings with the French agency. The review of the CTA is progressing. The trial will be conducted at the Henri Mondor Hospital in Paris where the Ethics Committee has already approved the study. Subject to approval by AFSSAPS, Oxford BioMedica expects the first patient to be treated in late 2007 or early 2008".

The more horses in the race, the more chance one will finish.

Neil.